Li-Zhi Liu

List of Publications by Year
in descending order

101 papers	4,120 citations	172457 29 h-index	128289 60 g-index
107 all docs	107 docs citations	107 times ranked	2889 citing authors

#	Article	IF	Citations
1	MRI of nasopharyngeal carcinoma: parapharyngeal subspace involvement has prognostic value and influences T-staging in the IMRT era. European Radiology, 2022, 32, 262-271.	4.5	8
2	Automatic location scheme of anatomical landmarks in 3D head MRI based on the scale attention hourglass network. Computer Methods and Programs in Biomedicine, 2022, 214, 106564.	4.7	3
3	Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis. JCO Precision Oncology, 2022, 6, e2100362.	3.0	1
4	Establishment and Validation of a Novel MRI Radiomics Feature-Based Prognostic Model to Predict Distant Metastasis in Endemic Nasopharyngeal Carcinoma. Frontiers in Oncology, 2022, 12, 794975.	2.8	1
5	Prognostic value of quantitative cervical nodal necrosis burden on MRI in nasopharyngeal carcinoma and its role as a stratification marker for induction chemotherapy. European Radiology, 2022, 32, 7710-7721.	4.5	1
6	Value of skull base invasion subclassification in nasopharyngeal carcinoma: implication for prognostic stratification and use of induction chemotherapy. European Radiology, 2022, 32, 7767-7777.	4.5	9
7	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2021, 113, 471-480.	6.3	17
8	Excessive vitamin B6 during treatment is related to poor prognosis of patients with nasopharyngeal carcinoma: A U-shaped distribution suggests low dose supplement. Clinical Nutrition, 2021, 40, 2293-2300.	5.0	3
9	Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma. Radiotherapy and Oncology, 2021, 155, 219-225.	0.6	21
10	Prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma: A retrospective study. Radiotherapy and Oncology, 2021, 156, 113-119.	0.6	1
11	Prognostic Value of Nodal Matting on <scp>MRI</scp> in Nasopharyngeal Carcinoma Patients. Journal of Magnetic Resonance Imaging, 2021, 53, 152-164.	3.4	12
12	Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma. IEEE Access, 2021, 9, 98701-98711.	4.2	2
13	The Effect on the Kidney in Patients With Anti-N-methyl D-aspartate Receptor Antibody Encephalitis. Frontiers in Neurology, 2021, 12, 601495.	2.4	0
14	Grading Soft Tissue Involvement in Nasopharyngeal Carcinoma Using Network and Survival Analyses: A Twoâ€Center Retrospective Study. Journal of Magnetic Resonance Imaging, 2021, 53, 1752-1763.	3.4	2
15	Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiotherapy and Oncology, 2021, 157, 114-121.	0.6	32
16	Differences in Radiomics Signatures Between Patients with Early and Advanced Tâ€Stage Nasopharyngeal Carcinoma Facilitate Prognostication. Journal of Magnetic Resonance Imaging, 2021, 54, 854-865.	3.4	8
17	Extent of paranasal sinus involvement and its prognostic value in nasopharyngeal carcinoma: Proposed modification in the current UICC/AJCC staging system. Radiotherapy and Oncology, 2021, 160, 221-227.	0.6	3
18	Surface-Based Falff: A Potential Novel Biomarker for Prediction of Radiation Encephalopathy in Patients With Nasopharyngeal Carcinoma. Frontiers in Neuroscience, 2021, 15, 692575.	2.8	8

#	Article	IF	Citations
19	Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma. Oral Oncology, 2021, 122, 105555.	1.5	3
20	Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers. BMC Cancer, 2021, 21, 1167.	2.6	12
21	Nodal grouping in nasopharyngeal carcinoma: prognostic significance, N classification, and a marker for the identification of candidates for induction chemotherapy. European Radiology, 2020, 30, 2115-2124.	4.5	29
22	Prognostic significance of quantitative metastatic lymph node burden on magnetic resonance imaging in nasopharyngeal carcinoma: A retrospective study of 1224 patients from two centers. Radiotherapy and Oncology, 2020, 151, 40-46.	0.6	21
23	New parameters of the 8th edition AJCC/UICC T category in nasopharyngeal carcinoma: Cervical vertebrae invasion and parotid gland invasion. Clinical and Translational Medicine, 2020, 10, e202.	4.0	1
24	Grading and prognosis of weight loss before and after treatment with optimal cutoff values in nasopharyngeal carcinoma. Nutrition, 2020, 78, 110943.	2.4	3
25	Prognostic value of MRIâ€determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Medicine, 2020, 9, 7100-7106.	2.8	11
26	Staging of T2 and T3 nasopharyngeal carcinoma: Proposed modifications for improving the current AJCC staging system. Cancer Medicine, 2020, 9, 7572-7579.	2.8	9
27	Machine Learning Analysis of Image Data Based on Detailed MR Image Reports for Nasopharyngeal Carcinoma Prognosis. BioMed Research International, 2020, 2020, 1-10.	1.9	15
28	A Nomogram for Predicting Distant Metastasis Using Nodal-Related Features Among Patients With Nasopharyngeal Carcinoma. Frontiers in Oncology, 2020, 10, 616.	2.8	13
29	Predicting poor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: Model constructed using pre-treatment MRI features of structured report template. Radiotherapy and Oncology, 2020, 148, 97-106.	0.6	12
30	10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. Oncologist, 2019, 24, e38-e45.	3.7	57
31	Paranasal sinus invasion suggested T4 classification of patients of nasopharyngeal carcinoma: A twoâ€center retrospective investigation. Head and Neck, 2019, 41, 4088-4097.	2.0	3
32	Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma. Cancer Communications, 2019, 39, 75.	9.2	27
33	Prognostic value of retropharyngeal lymph node metastasis laterality in nasopharyngeal carcinoma and a proposed modification to the UICC/AJCC N staging system. Radiotherapy and Oncology, 2019, 140, 90-97.	0.6	25
34	Elevated Plasma Homocysteine Levels in Anti-N-methyl-D-aspartate Receptor Encephalitis. Frontiers in Neurology, 2019, 10, 464.	2.4	6
35	Relationship of circulating tumor cells and Epsteinâ€“Barr virus DNA to progressionâ€free survival and overall survival in metastatic nasopharyngeal carcinoma patients. International Journal of Cancer, 2019, 145, 2873-2883.	5.1	38
36	Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups. European Radiology, 2019, 29, 5590-5599.	4.5	43

#	Article	IF	Citations
37	Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. Clinical Cancer Research, 2019, 25, 4271-4279.	7.0	234
38	Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: A double-center retrospective investigation. Radiotherapy and Oncology, 2019, 134, 37-43.	0.6	16
39	The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy. Radiotherapy and Oncology, 2019, 131, 35-44.	0.6	28
40	Proposed modifications and incorporation of plasma Epsteinâ€Barr virus DNA improve the TNM staging system for Epsteinâ€Barr virusâ€related nasopharyngeal carcinoma. Cancer, 2019, 125, 79-89.	4.1	143
41	Antiâ€epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Science, 2018, 109, 1609-1616.	3.9	11
42	Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. BMC Cancer, 2018, 18, 323.	2.6	18
43	Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis. Oral Oncology, 2018, 79, 40-46.	1.5	28
44	Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncology, The, 2018, 19, 382-393.	10.7	232
45	Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma. BMC Cancer, 2018, 18, 1276.	2.6	8
46	Cortical Surface Area Rather Than Cortical Thickness Potentially Differentiates Radiation Encephalopathy at Early Stage in Patients With Nasopharyngeal Carcinoma. Frontiers in Neuroscience, 2018, 12, 599.	2.8	17
47	Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A largeâ€scale cohort study. Cancer Science, 2018, 109, 1909-1919.	3.9	22
48	Ultrasoundâ€guided fine needle aspiration of retropharyngeal lymph nodes after radiotherapy for nasopharyngeal carcinoma: a novel technique for accurate diagnosis. Cancer Communications, 2018, 38, 1-8.	9.2	15
49	Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. European Journal of Cancer, 2017, 77, 117-126.	2.8	80
50	Radiation-induced abnormal cortical thickness in patients with nasopharyngeal carcinoma after radiotherapy. NeuroImage: Clinical, 2017, 14, 610-621.	2.7	40
51	Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. Oral Oncology, 2017, 75, 120-126.	1.5	12
52	Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes. Chinese Journal of Cancer, 2017, 36, 32.	4.9	9
53	Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis. Journal of Cancer, 2017, 8, 2587-2594.	2.5	6
54	Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. Journal of Cancer, 2017, 8, 3718-3724.	2.5	25

#	Article	IF	Citations
55	Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy. Journal of Cancer, 2017, 8, 371-377.	2.5	25
56	Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epsteinâ€“Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Chinese Journal of Cancer, 2017, 36, 98.	4.9	29
57	Significant value of 18F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Chinese Journal of Cancer, 2017, 36, 95.	4.9	25
58	Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma. Oncotarget, 2017, 8, 10594-10601.	1.8	5
59	Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget, 2016, 7, 24208-24216.	1.8	43
60	Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases. Journal of Cancer, 2016, 7, 1353-1359.	2.5	12
61	Prognostic Value of Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma with Low Pre-treatment Epstein-Barr Virus DNA: a Propensity-matched Analysis. Journal of Cancer, 2016, 7, 1465-1471.	2.5	14
62	1Î±,25(OH)2D3 Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through the Inhibition of Epithelialâ€“Mesenchymal Transition. International Journal of Molecular Sciences, 2016, 17, 1285.	4.1	34
63	The Impact of Clinical Stage on Radiation Doses to Organs at Risk Following Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma: A Prospective Analysis. Journal of Cancer, 2016, 7, 2157-2164.	2.5	5
64	Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy. Scientific Reports, 2016, 6, 22000.	3.3	58
65	Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. Oncologist, 2016, 21, 1369-1376.	3.7	50
66	Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis. Oral Oncology, 2016, 62, 78-84.	1.5	30
67	Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Scientific Reports, 2016, 6, 22326.	3.3	24
68	Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy. Scientific Reports, 2016, 6, 22200.	3.3	7
69	The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. Scientific Reports, 2016, 6, 24332.	3.3	22
70	The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Scientific Reports, 2016, 6, 24835.	3.3	52
71	Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chinese Journal of Cancer, 2016, 35, 103.	4.9	124
72	Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2). Health and Quality of Life Outcomes, 2016, 14, 76.	2.4	12

#	Article	IF	Citations
73	Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy. PLoS ONE, 2016, 11, e0166194.	2.5	7
74	Primary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patients. Oncotarget, 2016, 7, 14963-14972.	1.8	4
75	Fine-needle aspiration of a retropharyngeal lymph node guided by endoscopic ultrasonography. Endoscopy, 2015, 47, E449-E450.	1.8	24
76	Prognostic value of parotid lymph node metastasis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Scientific Reports, 2015, 5, 13919.	3.3	10
77	Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis. BMC Cancer, 2015, 15, 709.	2.6	29
78	Prognostic Value of Classifying Parapharyngeal Extension in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging. BioMed Research International, 2015, 2015, 1-8.	1.9	3
79	Comorbidity predicts poor prognosis in nasopharyngeal carcinoma: Development and validation of a predictive score model. Radiotherapy and Oncology, 2015, 114, 249-256.	0.6	21
80	Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?. BMC Cancer, 2015, 15, 305.	2.6	9
81	Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiotherapy and Oncology, 2015, 116, 167-173.	0.6	14
82	Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 2864-2873.	4.1	80
83	Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0130620.	2.5	21
84	Prognostic Value and Staging Classification of Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy. PLoS ONE, 2014, 9, e108375.	2.5	35
85	Nasopharyngeal carcinoma with paranasal sinus invasion: the prognostic significance and the evidence-based study basis of its T-staging category according to the AJCC staging system. BMC Cancer, 2014, 14, 832.	2.6	20
86	MRI-detected skull-base invasion. Strahlentherapie Und Onkologie, 2014, 190, 905-911.	2.0	13
87	Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 110, 404-408.	0.6	24
88	Proposed Lymph Node Staging System Using the International Consensus Guidelines for Lymph Node Levels Is Predictive for Nasopharyngeal Carcinoma Patients From Endemic Areas Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 249-256.	0.8	65
89	Prognostic Value of Subclassification Using MRI in the T4 Classification Nasopharyngeal Carcinoma Intensity-Modulated Radiotherapy Treatment. International Journal of Radiation Oncology Biology Physics, 2012, 84, 196-202.	0.8	41
90	The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiotherapy and Oncology, 2012, 104, 331-337.	0.6	104

#	Article	IF	Citations
91	Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma?. Radiotherapy and Oncology, 2012, 104, 294-299.	0.6	114
92	Grading of MRIâ€detected skullâ€base invasion in nasopharyngeal carcinoma and its prognostic value. Head and Neck, 2011, 33, 1309-1314.	2.0	30
93	How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results inÂNasopharyngeal Carcinoma Patients?. International Journal of Radiation Oncology Biology Physics, 2011, 80, 661-668.	0.8	567
94	Radiologic Criteria of Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma Treated with Radiation Therapy. Radiology, 2010, 255, 605-612.	7.3	79
95	Prognostic impact of magnetic resonance imagingâ€detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer, 2009, 115, 1995-2003.	4.1	58
96	Re-Evaluation of 6th Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement Based on Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1326-1334.	0.8	236
97	Biphasic pulmonary blastoma with metastasis to adjacent rib: one case report. Chinese-German Journal of Clinical Oncology, 2008, 7, 670-672.	0.1	0
98	Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging. Cancer, 2008, 113, 347-354.	4.1	119
99	How Does Magnetic Resonance Imaging Influence Staging According to AJCC Staging System for Nasopharyngeal Carcinoma Compared With Computed Tomography?. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1368-1377.	0.8	145
100	The N Staging System in Nasopharyngeal Carcinoma with Radiation Therapy Oncology Group Guidelines for Lymph Node Levels Based on Magnetic Resonance Imaging. Clinical Cancer Research, 2008, 14, 7497-7503.	7.0	131
101	Magnetic resonance imaging of retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: Patterns of spread. International Journal of Radiation Oncology Biology Physics, 2006, 66, 721-730.	0.8	105